

# **NUVAXOVID (TM)**

Substance key: REG013141 Version:1.0 (United States of America) Revision Date: 08-05-2025

#### **SECTION 1. IDENTIFICATION**

Product name: NUVAXOVID (TM)

Manufacturer or supplier's details

Company : Sanofi

Street address : 46-48 avenue de la Grande-Armée

(FR) 75017 Paris

Telephone : +33153774000

Telefax : +33153774133

Safety data sheet created by:

Sanofi Global Product Stewardship (product-stewardship-global@sanofi.com)

Emergency telephone number : + 33 1 45 42 59 59 (ORFILA)

#### Recommended use of the chemical and restrictions on use

Recommended use : Drug product for medical use.

This document, established by Sanofi on a voluntary basis, aims at providing available information on the substances contained in our products and on the related risk management

measures.

This document is intended for use in the workplace and shall not be used in place of package inserts or other prescribing information, nor in place of any mandatory document (e.g SDS within the meaning of the REACH Regulation).

Although the information contained in the document has been prepared based on the best of our knowledge and is accurate as of the date shown on the document, such document is provided «as is», without any warranty, either expressed or

implied.

#### **SECTION 2. HAZARDS IDENTIFICATION**

# GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Not a hazardous substance or mixture.

### **GHS** label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required, Labeling of the finished drug product is not required according to OSHA 29 CFR 1910.1200.

#### Other hazards

None known.

Physical, chemical and toxicological hazards

: Avoid contact with skin and eyes

#### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

Vaccine using SARS-CoV-2 Spike protein prepared in insect

Product Description cells by recombinant technology

Page: 1/11 Print Date: 08-06-2025



# **NUVAXOVID (TM)**

Substance key: REG013141 Version:1.0 (United States of America) Revision Date: 08-05-2025

#### Components

No hazardous ingredients

#### **SECTION 4. FIRST AID MEASURES**

General advice During clinical use, seek medical advice for accidental

exposure if symptoms develop.

If accidental exposure occurs during bulk drug handling, seek

medical advice immediately.

If inhaled Inhalation during clinical use is not likely.

If aerosols/mists inhaled seek immediate medical assistance.

In case of skin contact Rinse immediately with plenty of water for at least 15 minutes.

If skin irritation or other syptoms occur seek medical advice

Rinse immediately with plenty of water, also under the eyelids, In case of eye contact

for at least 15 minutes.

Get immediate medical advice/ attention. Get immediate medical advice/ attention.

If swallowed Do NOT induce vomiting.

Rinse mouth with water.

If a person vomits when lying on his back, place him in the

recovery position.

Most important symptoms and effects, both acute and

No information available. No information available.

delayed

Notes to physician Treat symptomatically.

#### SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media Use extinguishing measures that are appropriate to local

circumstances and the surrounding environment.

Use water spray, alcohol-resistant foam, dry chemical or

carbon dioxide.

Unsuitable extinguishing

media

Do NOT use water jet.

Hazardous combustion

products

Carbon oxides

Further information Prevent fire extinguishing water from contaminating surface

water or the ground water system.

Use extinguishing measures that are appropriate to local

circumstances and the surrounding environment.

Fire residues and contaminated fire extinguishing water must

be disposed of in accordance with local regulations.

Special protective equipment:

for firefighters

Wear an approved positive pressure self-contained breathing

apparatus in addition to standard fire fighting gear.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures

No personal respiratory protective equipment normally

required.

Safety glasses with side-shields

Wear suitable gloves.

Wear suitable protective clothing.

Only qualified personnel equipped with suitable protective

equipment may intervene.

Environmental precautions Prevent further leakage or spillage.

> Print Date: 08-06-2025 Page: 2/11



**NUVAXOVID (TM)** 

Substance key: REG013141 Version:1.0 (United States of America) Revision Date: 08-05-2025

Do not let product enter drains.

Methods and materials for containment and cleaning up Soak up with inert absorbent material (e.g. sand, silica gel,

acid binder, universal binder, sawdust).

Sweep up and shovel into suitable containers for disposal.

Close and label thoroughly.

Elimination of recovered

materials

Deliver to the Environmental service of the factory or to any

specialized and approved disposal company.

#### **SECTION 7. HANDLING AND STORAGE**

Advice on protection against

fire and explosion

To avoid ignition of vapours by static electricity discharge, all

metal parts of the equipment must be grounded. Keep away from sources of ignition - No smoking.

Advice on safe handling Follow handlng practices for the Risk Group (RG 1-4) and

Biosafety Level(BSL 1-4) as established by local, regional or

country authorities.

For quality purposes, store in locations meeting the storage

temperature and conditions identified

Further information on

storage conditions

Keep tightly closed in a dry and cool place.

Keep away from direct sunlight.

Storage temperature Recommended storage temperature: +2°C to +8°C.

#### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Components with workplace control parameters

**Engineering measures** Follow engineering controls established by internal

engineering standards, recognized and generally accepted

good engineering practices (RAGAGEP) and/or

organizations/agencies considered an authority (e.g National Institute of Health, World Health) on biosafety engineering

controls.

#### Personal protective equipment

Respiratory protection

Usually, no respiratory protection required.

Hand protection

Material Nitrile rubber Rate of permeability > 480 min Glove thickness > 0.1 mm

Protective glove compatibility should be verified with the Remarks

Glove-Supplier

Eye protection Safety glasses with side shields conforming to ANSI Z.87

Skin and body protection Protective measures

Wear suitable protective clothing. Avoid contact with skin and eyes.

A workplace risk assessment must be carried out in order to determine the correct engineering control measures and

personal protective equipment.

: When using, do not eat, drink or smoke. Hygiene measures

Keep away from foodstuffs and beverages.

Print Date: 08-06-2025 Page: 3/11



**NUVAXOVID (TM)** 

Substance key: REG013141 Version:1.0 (United States of America) Revision Date: 08-05-2025

Wash hands before breaks and at the end of workday.

Laboratory

Respiratory protection : Usually, no respiratory protection required.

Hand protection : Nitrile rubber

Layer thickness > 0.11 mm. Breakthrough time > 480 min.

Eye/face protection : Safety glasses with side shields conforming to ANSI Z.87

Body Protection : Wear suitable protective clothing.

Hygiene measures : Wash hands before breaks and at the end of workday.

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Form : solution

Physical state : liquid (68 °F, 1,013 hPa)

Colour : opalescent

Odour : No data available

Odour Threshold : No data available

pH : not determined

Melting point/range : not determined

Boiling point : not determined

Flash point : not determined

Upper explosion limit / Upper

flammability limit

not determined

Lower explosion limit / Lower

flammability limit

not determined

Vapour pressure : not determined

Relative vapour density : not determined

Density : not determined

Page: 4/11 Print Date: 08-06-2025



Substance key: REG013141 Version:1.0 (United States of America) Revision Date: 08-05-2025



Solubility(ies)

Water solubility : not determined

Solubility in other solvents : not determined

Partition coefficient: n-

octanol/water

not determined

Ignition temperature : not determined

Auto-ignition temperature : not determined

Decomposition temperature : not determined

Lower explosion limit : not determined

Upper explosion limit : not determined

Minimum ignition energy : not determined

Viscosity

Viscosity, dynamic : not determined

Viscosity, kinematic : not determined

Impact sensitivity : not determined

### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : None known. Possibility of hazardous : None known.

reactions

Conditions to avoid : None known. Incompatible materials : None known.

Hazardous decomposition

products

: No hazardous decomposition products are known.

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

#### **Acute toxicity**

Product name	Test Type	Species	Result	Method, Symptoms	Remarks
(CAS-No.)					
NUVAXOVID (TM)	Acute oral toxicity	Acute toxicity	> 5,000 mg/kg	Method: Calculation	Source: Calculated

Page: 5/11	Print Date: 08-06-2025



# **NUVAXOVID (TM)**

Substance key: REG013141 Version:1.0 (United States of America) Revision Date: 08-05-2025

	estimate		method	
--	----------	--	--------	--

#### Skin corrosion/irritation

Ī	Product name	Species	Result	Method, Symptoms	Remarks
	(CAS-No.)				
Ī	NUVAXOVID (TM)				No data available for mixture.

# Serious eye damage/eye irritation

Ī	Product name	Species	Result	Method, Symptoms	Remarks
	(CAS-No.)				
ĺ	NUVAXOVID (TM)				No data available for mixture.

# Respiratory or skin sensitisation

Product name	Species	Result	Method, Symptoms	Remarks
(CAS-No.)				
NUVAXOVID (TM)				No data available for mixture.

# Carcinogenicity

IARC No component of this product present at levels greater than or equal to 0.1% is identified as

probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of

regulated carcinogens.

NTP No component of this product present at levels greater than or equal to 0.1% is identified as a

known or anticipated carcinogen by NTP.

Carcinogenicity/Germ cell mutagenicity/Reproductive toxicity - Assessment

Product name (CAS-No.)	Carcinogenicity	Germ cell mutagenicity	Reproductive toxicity	Remarks
NUVAXOVID (TM)	not determined	not determined	Reproduction: not determined Teratogenicity: not determined	

# STOT - single exposure

Product name	Test Type	Exposure routes	Target Organs	Assessment	Remarks
(CAS-No.)					
NUVAXOVID (TM)	STOT-single exposure				No data available
					for mixture.

#### STOT - repeated exposure

Product name (CAS-No.)	Test Type	Exposure routes	Target Organs	Assessment	Remarks
NUVAXOVID (TM)	STOT - repeated exposure				No data available for mixture.

# **Aspiration toxicity**

Product name	Test Type	Result	Remarks
(CAS-No.)			
NUVAXOVID (TM)	Aspiration toxicity	No data available for mixture.	
	•		

#### 11.2 Information on other hazards

Page: 6/11	Print Date: 08-06-2025
Page: 6/11	Print Date: 08-06-2



# **NUVAXOVID (TM)**

Substance key: REG013141 Version:1.0 (United States of America) Revision Date: 08-05-2025

#### **SECTION 12. ECOLOGICAL INFORMATION**

# 12.1 Toxicity

Product name (CAS-No.)	Test Type	Species	Result	Method	Remarks
NUVAXOVID (TM)	Toxicity to fish				No data available for mixture.
NUVAXOVID (TM)	Toxicity to daphnia and other aquatic invertebrates				No data available for mixture.
NUVAXOVID (TM)	Toxicity to algae/aquatic plants				No data available for mixture.
NUVAXOVID (TM)	Toxicity to microorganisms				No data available for mixture.
NUVAXOVID (TM)	Toxicity to soil dwelling organisms				No data available for mixture.

# 12.2 Persistence and degradability

Product name	Test Type	Conditions	Result	Method	Remarks
(CAS-No.)					
NUVAXOVID (TM)	Biodegradability				No data available
,	•				for mixture.

# 12.3 Bioaccumulative potential

Product name	Test Type	Conditions	Result	Method	Remarks
(CAS-No.)					
NUVAXOVID (TM)	Bioaccumulation				No data available
					for mixture.

#### 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

# 12.6 Endocrine disrupting properties

#### 12.7 Other adverse effects

Product name (CAS-No.)	Test Type	Result	Remarks
NUVAXOVID (TM)	Ozone-Depletion Potential	Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances	This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

# **SECTION 13. DISPOSAL CONSIDERATIONS**

#### Disposal methods

Waste from residues : Dispose of contents/ container to an approved waste disposal

plant.

Page: 7/11 Print Date: 08-06-2025



# **NUVAXOVID (TM)**

Substance key: REG013141 Version:1.0 (United States of America) Revision Date: 08-05-2025

Contaminated packaging : Dispose of contents/ container to an approved waste disposal

plant.

Do not re-use empty containers.

#### **SECTION 14. TRANSPORT INFORMATION**

#### International Regulations

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

**National Regulations** 

#### **SECTION 15. REGULATORY INFORMATION**

#### EPCRA - Emergency Planning and Community Right-to-Know Act

#### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

Components	CAS-No.	Component TPQ (lbs)
SARA 311/312 Hazards	: No SARA Hazards	

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

#### Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

#### Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

The following Hazardous Chemicals are listed under the U.S. CleanWater Act, Section 311, Table 117.3:

Sodium Phospate, 7782-85-6 >= 0.1 - < 1 %

Dibasic Heptahydrate

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

#### **US State Regulations**

#### Massachusetts Right To Know

No components are subject to the Massachusetts Right to Know Act.

### Pennsylvania Right To Know

Water 7732-18-5 Sodium Phospate, Dibasic Heptahydrate 7782-85-6

Maine Chemicals of High Concern

SARS-CoV-2 recombinant spike protein Not Assigned

# **Vermont Chemicals of High Concern**

Page: 8/11 Print Date: 08-06-2025



#### **NUVAXOVID (TM)**

Substance key: REG013141 Version:1.0 (United States of America) Revision Date: 08-05-2025

SARS-CoV-2 recombinant spike protein

Not Assigned

#### Washington Chemicals of High Concern

SARS-CoV-2 recombinant spike protein

Not Assigned

#### California Prop. 65

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

TCSI : Not in compliance with the inventory

TSCA : Product contains substance(s) not listed on TSCA inventory.

AIIC : Not in compliance with the inventory

DSL : This product contains the following components that are not

on the Canadian DSL nor NDSL.

ENCS : Not in compliance with the inventory

ISHL : Not in compliance with the inventory

KECI : Not in compliance with the inventory

PICCS : Not in compliance with the inventory

IECSC : Not in compliance with the inventory

NZIoC : Not in compliance with the inventory

TECI: Not in compliance with the inventory

#### **TSCA list**

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

### **SECTION 16. OTHER INFORMATION**

# Full text of other abbreviations

AllC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS -

Page: 9/11 Print Date: 08-06-2025



**NUVAXOVID (TM)** 

Substance key: REG013141 Version:1.0 (United States of America) Revision Date: 08-05-2025

Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx -Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA -International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO -International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO -International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 08-05-2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN

Page: 10/11 Print Date: 08-06-2025



NUVAXOVID (TM)
Substance key: REG013141 Version:1.0 (United States of America) Revision Date: 08-05-2025

# **Definition of Sanofi-OEB:**

OEB is the occupational exposure band with the following levels:

Occupational Exposure Band	Occupational Exposure Level
OEB 1	> 1000 µg/m³
OEB 2	100 - 1000 μg/m³
OEB 3	10 – 100 μg/m³
OEB 4	1 – 10 μg/m³
OEB 5	< 1 µg/m³

Additional notations may be applied as suffixes to the OEL/OEB and are used to communicate additional information that is not directly indicated by the OEL/OEB classifications. This information is necessary to perform an efficient risk assessment and determine the correct exposure controls. The meanings of the suffixes is explained in this way:

Notation/Suffixes	Danger
G1	Reprotoxic hazard for pregnant women. Exposure below the OEL is acceptable.
G2	Reprotoxic hazard for pregnant women. Exposure even below the OEL is not acceptable.
Sr	Respiratory sensitization hazard with serious potential consequences (anaphylactic reactions).
Sk	Specific dermal hazard (High dermal absorption / Danger of skin sensitization).
Cor	Corrosive compound - Important dermal and ocular hazard If corrosive compounds.

Page: 11/11 Print Date: 08-06-2025